From the New York Stock Exchange, AstraZeneca CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more
- Jun 5
- 1 min read
In New York to ring the open bell in celebration of the listing of the AstraZeneca's ordinary shares on the NYSE earlier this year, he discusses M&A, PD-1 x VEGF, PD-1 x TIGIT, Baxfendy, and the company's efforts in obesity ahead of this weekend's American Diabetes Association Scientific Sessions.
.png){kind=logo}